Please login to the form below

Not currently logged in
Email:
Password:

canagliflozin

This page shows the latest canagliflozin news and features for those working in and with pharma, biotech and healthcare.

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

from AstraZeneca’s Farxiga/Forxiga (dapagliflozin) and Johnson &Johnson’s Invokana (canagliflozin).

Latest news

More from news
Approximately 8 fully matching, plus 52 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....